search
Back to results

Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression (tVNS_MDD_Sex)

Primary Purpose

Major Depressive Disorder

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
active tVNS
Sham tVNS
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Major Depressive Disorder focused on measuring Autonomic Nervous System, Transcutaneous Vagus Nerve Stimulation, Stress Response Circuitry, Functional Magnetic Resonance Imaging, Sex Differences

Eligibility Criteria

50 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Current or past diagnosis of recurrent Major Depressive Disorder

Exclusion Criteria:

  • History of neuroleptic use
  • Any psychiatric disorder involving a history of psychosis (e.g. schizophrenia, bipolar I disorder)
  • Active suicidal ideation with intent and/or plan or history of a suicide attempt within the last year
  • Moderate or severe substance use disorder within the past 12 months
  • Diagnosis of significant cardiovascular or cerebrovascular disease (e.g. congestive heart failure, stroke, cardiac conduction disorders, history of asystole or non-sustained ventricular tachycardia)
  • Diseases affecting the CNS (e.g. MS, epilepsy, neurodegenerative diseases, etc.)
  • Traumatic brain injury with cognitive sequelae
  • MRI or tVNS contraindications (e.g. claustrophobia, metallic implants or devices)
  • Pregnancy (uncommon, given the age of this cohort is 50+ years) due to unknown health risks for the fetus

Sites / Locations

  • Massachusetts General HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Active tVNS

Sham tVNS

Arm Description

Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle

Sham transcutaneous vagus nerve stimulation on the left auricle

Outcomes

Primary Outcome Measures

Brain activity during functional magnetic resonance imaging (fMRI)
Changes in fMRI BOLD signal (percent BOLD signal change) of the stress response circuitry between active and sham tVNS.
Cardiac autonomic function during functional magnetic resonance imaging (fMRI)
Changes in cardiac autonomic function (High Frequency power-Heart Rate Variability) between active and sham tVNS.

Secondary Outcome Measures

Change in serum cortisol levels
Changes in serum cortisol levels from baseline to post-stimulation will be assessed and compared between active and sham tVNS
Change in serum levels of pro-inflammatory cytokines
Changes in serum levels of proinflammatory cytokines (IL1B, IL6, TNF alfa) from baseline to post-stimulation will be assessed and compared between active and sham tVNS
Change in depressive symptoms assessed by the Beck Depression Inventory
Changes from baseline to post-stimulation in the score of the Beck Depression Inventory will be compared between active and sham tVNS. (Beck depression inventory minimum score= 0, maximum score= 63; higher total scores indicate more severe depressive symptoms)

Full Information

First Posted
June 17, 2020
Last Updated
March 13, 2023
Sponsor
Massachusetts General Hospital
Collaborators
National Institute of Mental Health (NIMH)
search

1. Study Identification

Unique Protocol Identification Number
NCT04448327
Brief Title
Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression
Acronym
tVNS_MDD_Sex
Official Title
Sex-Dependent Impact of Transcutaneous Vagal Nerve Stimulation on the Stress Response Circuitry and Autonomic Dysregulation in Major Depression
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 29, 2021 (Actual)
Primary Completion Date
July 15, 2024 (Anticipated)
Study Completion Date
November 15, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
National Institute of Mental Health (NIMH)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will identify the sex-dependent impact of expiratory-gated transcutaneous vagus nerve stimulation (tVNS) on the modulation of the stress response circuitry and associated physiology in major depressive disorder (MDD). We will evaluate a sample of 80 adults with recurrent MDD randomized to receive active or sham expiratory-gated tVNS during a functional magnetic resonance imaging (fMRI) session, with simultaneous mood and physiological assessments. We hypothesize that expiratory-gated tVNS will effectively modulate, in a sex-dependent manner, specific brainstem-cortical pathways of the stress circuitry and attenuate physiological deficits in MDD.
Detailed Description
Major depressive disorder (MDD) is a leading cause of morbidity and disability worldwide with abnormalities in the stress response circuitry and central autonomic network. Many of these regions are sexually dimorphic and related with sex differences in mood and hypothalamic-pituitary-adrenal (HPA) axis modulation, the dysregulation of which is associated with alterations of hormone and immune responses to stress, autonomic dysfunction and increased cardiovascular risk. The primary goal of this study is to use non-invasive neuromodulatory stimulation of the vagus to target the circuitry associated with stress-immune function and map its neuroanatomic and physiological effects in MDD by sex. Vagal nerve stimulation (VNS), FDA-approved for MDD, modulates brain circuitry implicated in mood/anxiety and autonomic regulation, however, it is implanted and thus invasive. We propose the use of a physiologically-enhanced transcutaneous VNS (tVNS) as a low risk, non-invasive, and inexpensive alternative. While tVNS has had beneficial effects on depressive symptomatology and autonomic regulation, current stimulation parameters are based on historical iVNS data that included mostly male populations. We propose that tVNS effects on the regulation of specific brainstem-cortical pathways is modulated by sex. Moreover, as the dorsal medullary vagal system operates in tune with respiration, we recently demonstrated that tVNS can be optimized by gating stimulation to respiration. Thus, this study proposes to identify the sex-dependent impact of expiratory-gated tVNS on the modulation of stress response circuitry alterations and physiological dysregulation of recurrent MDD. We will evaluate a sample of 80 adults with recurrent MDD randomized to receive active tVNS or sham stimulation during a functional magnetic resonance imaging (fMRI) session. The fMRI session will include a stress challenge designed to elicit a sympatho-excitatory state, with simultaneous mood and physiological assessments, including hormonal and dynamic cardiovagal heart rate variability (HRV) evaluations. We hypothesize that expiratory-gated tVNS will effectively modulate specific brainstem-cortical pathways of the stress response circuitry and will attenuate physiological deficits of recurrent MDD patients. We further hypothesize that tVNS will impact brain activity and physiology in sex-dependent ways.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Depressive Disorder
Keywords
Autonomic Nervous System, Transcutaneous Vagus Nerve Stimulation, Stress Response Circuitry, Functional Magnetic Resonance Imaging, Sex Differences

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Active tVNS
Arm Type
Experimental
Arm Description
Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle
Arm Title
Sham tVNS
Arm Type
Sham Comparator
Arm Description
Sham transcutaneous vagus nerve stimulation on the left auricle
Intervention Type
Device
Intervention Name(s)
active tVNS
Other Intervention Name(s)
transcutaneous vagus nerve stimulation
Intervention Description
non-painful electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session
Intervention Type
Device
Intervention Name(s)
Sham tVNS
Other Intervention Name(s)
transcutaneous vagus nerve stimulation
Intervention Description
Sham stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session
Primary Outcome Measure Information:
Title
Brain activity during functional magnetic resonance imaging (fMRI)
Description
Changes in fMRI BOLD signal (percent BOLD signal change) of the stress response circuitry between active and sham tVNS.
Time Frame
1 hour
Title
Cardiac autonomic function during functional magnetic resonance imaging (fMRI)
Description
Changes in cardiac autonomic function (High Frequency power-Heart Rate Variability) between active and sham tVNS.
Time Frame
1 hour
Secondary Outcome Measure Information:
Title
Change in serum cortisol levels
Description
Changes in serum cortisol levels from baseline to post-stimulation will be assessed and compared between active and sham tVNS
Time Frame
2 hours
Title
Change in serum levels of pro-inflammatory cytokines
Description
Changes in serum levels of proinflammatory cytokines (IL1B, IL6, TNF alfa) from baseline to post-stimulation will be assessed and compared between active and sham tVNS
Time Frame
2 hours
Title
Change in depressive symptoms assessed by the Beck Depression Inventory
Description
Changes from baseline to post-stimulation in the score of the Beck Depression Inventory will be compared between active and sham tVNS. (Beck depression inventory minimum score= 0, maximum score= 63; higher total scores indicate more severe depressive symptoms)
Time Frame
2 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Current or past diagnosis of recurrent Major Depressive Disorder Exclusion Criteria: History of neuroleptic use Any psychiatric disorder involving a history of psychosis (e.g. schizophrenia, bipolar I disorder) Active suicidal ideation with intent and/or plan or history of a suicide attempt within the last year Moderate or severe substance use disorder within the past 12 months Diagnosis of significant cardiovascular or cerebrovascular disease (e.g. congestive heart failure, stroke, cardiac conduction disorders, history of asystole or non-sustained ventricular tachycardia) Diseases affecting the CNS (e.g. MS, epilepsy, neurodegenerative diseases, etc.) Traumatic brain injury with cognitive sequelae MRI or tVNS contraindications (e.g. claustrophobia, metallic implants or devices) Pregnancy (uncommon, given the age of this cohort is 50+ years) due to unknown health risks for the fetus
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ronald G Garcia, MD, PhD
Phone
617-643-4265
Email
rgarciagomez@mgh.harvard.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Vitaly Napadow, PhD
Phone
617-724-3402
Email
vitaly@mgh.harvard.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ronald G Garcia, MD, PhD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Charlestown
State/Province
Massachusetts
ZIP/Postal Code
02129
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ronald G Garcia, MD, PhD
Phone
617-643-4265
Email
rgarciagomez@mgh.harvard.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression

We'll reach out to this number within 24 hrs